CN114875074B - 提高多克隆兔抗体产生的方法 - Google Patents
提高多克隆兔抗体产生的方法 Download PDFInfo
- Publication number
- CN114875074B CN114875074B CN202210684243.6A CN202210684243A CN114875074B CN 114875074 B CN114875074 B CN 114875074B CN 202210684243 A CN202210684243 A CN 202210684243A CN 114875074 B CN114875074 B CN 114875074B
- Authority
- CN
- China
- Prior art keywords
- rabbit
- antibody
- sequence
- sgrna
- female
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 15
- 230000016784 immunoglobulin production Effects 0.000 title abstract description 6
- 235000013601 eggs Nutrition 0.000 claims abstract description 13
- 210000002257 embryonic structure Anatomy 0.000 claims abstract description 11
- 238000000520 microinjection Methods 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 17
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 210000003101 oviduct Anatomy 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 10
- 230000012173 estrus Effects 0.000 claims description 9
- 238000011144 upstream manufacturing Methods 0.000 claims description 9
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 8
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000011010 flushing procedure Methods 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 6
- 102000053602 DNA Human genes 0.000 claims description 5
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 claims description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 5
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 206010042573 Superovulation Diseases 0.000 claims description 4
- 238000000137 annealing Methods 0.000 claims description 4
- 238000004925 denaturation Methods 0.000 claims description 4
- 230000036425 denaturation Effects 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000003651 drinking water Substances 0.000 claims description 4
- 235000020188 drinking water Nutrition 0.000 claims description 4
- 230000008217 follicular development Effects 0.000 claims description 4
- 230000013011 mating Effects 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 4
- 238000011587 new zealand white rabbit Methods 0.000 claims description 4
- 238000012257 pre-denaturation Methods 0.000 claims description 4
- 230000035935 pregnancy Effects 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 210000003855 cell nucleus Anatomy 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 229960004407 chorionic gonadotrophin Drugs 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 240000007711 Peperomia pellucida Species 0.000 claims description 2
- 210000000683 abdominal cavity Anatomy 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 229940125644 antibody drug Drugs 0.000 abstract description 3
- 238000009509 drug development Methods 0.000 abstract description 2
- 238000003205 genotyping method Methods 0.000 abstract 1
- 108091033409 CRISPR Proteins 0.000 description 13
- 230000035772 mutation Effects 0.000 description 9
- 238000013461 design Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100112111 Caenorhabditis elegans cand-1 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- -1 phosphoramidite triester Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
一种提高多克隆兔抗体产生的方法,属于生物技术领域。本发明的目的是创建一种可以高产抗体兔,以获得效价更高的多克隆抗体,为抗体的进一步研发提供技术支持的提高多克隆兔抗体产生的方法。本发明步骤是:获得足够数量兔受精卵,胚胎显微注射,兔基因型鉴定。本发明促进抗体制备技术的发展,引领抗体药物研发的新方向,可以高产抗体兔,以获得效价更高的多克隆抗体,为抗体的进一步研发提供技术支持。
Description
技术领域
本发明属于生物技术领域。
背景技术
与各种来源的抗体相比,兔源抗体有更广泛的抗体谱,免疫球蛋白结构简单,且具有更高特异性和亲和力。近年来,CRISPR/Cas9基因编辑技术已为高效率基因编辑开辟了一条全新的思路,极大的推动了基因修饰动物的发展,并成功应用于斑马鱼、小鼠、大鼠、兔、猪、猴子等多个物种。
发明内容
本发明的目的是创建一种可以高产抗体兔,以获得效价更高的多克隆抗体,为抗体的进一步研发提供技术支持的提高多克隆兔抗体产生的方法。
本发明步骤是:
步骤一、获得足够数量兔受精卵:采用超数排卵方案,选用雌性新西兰大白兔,在发情期内经肌肉注射促卵泡激素50 IU,以促进卵泡发育成熟,每12小时注射一次,连续注射3天;最后一次注射后,与公兔进行交配,将交配成功的供体母兔通过耳缘静脉注射100IU人绒毛膜促性腺激素;在注射18-20h后,取出卵巢和输卵管放于培养皿中,使用冲卵液DPBS-BSA冲出受精胚胎,将胚胎移入培养液EBSS中,置于38.5℃,5% CO2饱和湿度的培养箱内孵育待用;
步骤二、胚胎显微注射:将体外合成的50ng/UL 的FcγRIIb-sgRNA、单链DNA和200ng/UL 的Cas9mRNA,短暂离心后混合,吸出3μL至注射针中,进行胚胎细胞核注射,注射后的受精卵30-50枚移植到同期发情的受体母兔输卵管中,对代孕母兔提供充足的饲料和饮水,保持干净饲养环境,规范化饲养,妊娠至20天后,转至产房饲养至预产期;
步骤三、兔基因型鉴定:提取组织的DNA,进行PCR及测序,确定基因型,
PCR 引物: 上游引物:GGAGGAAGTAAATAGTGCACAGA
下游引物:GGGACTAGACTTTATCTTGGTGTC
PCR反应体系
模板 1ul
上游引物 1ul
下游引物 1ul
2X taqplus 12.5 ul
二馏水 9.5ul
反应的条件:95℃预变性5min;95 ℃变性30s,58℃退火30s,72℃延伸27s;35个循环;72℃ 延伸5min;
PCR产物测序,若在sgRNA序列的第18位的T突变成C,则证明获得单碱基突变。
本发明针对兔FcγRIIb基因序列,针对人类SLE疾病位点设计突变,设计特异性sgRNA的序列为SEQ ID NO.1。
本发明单链设计是依据sgRNA序列,在FcγRIIb基因序列上sgRNA序列的左右选择各加上55bp,并对sgRNA上的第18位的T突变成C,将Cas9识别的PAM(NGG)突变,通过同义突变将TGG突变成TAG,使得寡链不再被cas9识别靶向,获得的特异性的寡聚核苷酸单链序列为SEQ ID NO.2。
本发明鉴定兔的基因型的鉴定引物F序列为SEQ ID NO.3,鉴定兔的基因型的鉴定引物R序列为SEQ ID NO.4。
本发明促进抗体制备技术的发展,引领抗体药物研发的新方向,可以高产抗体兔,以获得效价更高的多克隆抗体,为抗体的进一步研发提供技术支持。
附图说明
图1是本发明基因敲除情况的测序峰图;
图2是兔瘟疫苗免疫后正常兔和基因编辑兔血清中IgG的含量。
具体实施方式
抗体药物是现代生物医药产业的主力军,目前占全球生物药物市场的50%,是生物医药产业增长最快的细分领域,抗体的应用广泛,在医疗、科研等方面发挥着重要作用,抗体产业的科研价值和经济价值都很相当可观,但它们的有限供应(效价低)削弱了它们的实用性。本发明提供一种制备高产抗体兔的方法,促进抗体制备技术的发展,引领抗体药物研发的新方向。
本发明步骤是:
步骤一、获得足够数量兔受精卵:采用超数排卵方案,选用雌性新西兰大白兔,在发情期内经肌肉注射促卵泡激素50 IU,以促进卵泡发育成熟,每12小时注射一次,连续注射3天;最后一次注射后,与公兔进行交配,将交配成功的供体母兔通过耳缘静脉注射100IU人绒毛膜促性腺激素;在注射18-20h后,取出卵巢和输卵管放于培养皿中,使用冲卵液DPBS-BSA冲出受精胚胎,将胚胎移入培养液EBSS中,置于38.5℃,5% CO2饱和湿度的培养箱内孵育待用;
步骤二、胚胎显微注射:将体外合成的50ng/UL 的FcγRIIb-sgRNA、单链DNA和200ng/UL 的Cas9mRNA,短暂离心后混合,吸出3μL至注射针中,进行胚胎细胞核注射,注射后的受精卵30-50枚移植到同期发情的受体母兔输卵管中,对代孕母兔提供充足的饲料和饮水,保持干净饲养环境,规范化饲养,妊娠至20天后,转至产房饲养至预产期;
步骤三、兔基因型鉴定:提取组织的DNA,进行PCR及测序,确定基因型,
PCR 引物: 上游引物:GGAGGAAGTAAATAGTGCACAGA
下游引物:GGGACTAGACTTTATCTTGGTGTC
PCR反应体系
模板 1ul
上游引物 1ul
下游引物 1ul
2X taqplus 12.5 ul
二馏水 9.5ul
反应的条件:95℃预变性5min;95 ℃变性30s,58℃退火30s,72℃延伸27s;35个循环;72℃ 延伸5min;
PCR产物测序,若在sgRNA序列的第18位的T突变成C,则证明获得单碱基突变。
本发明针对兔FcγRIIb基因序列,针对人类SLE疾病位点设计突变,设计特异性sgRNA的序列为SEQ ID NO.1。
本发明单链设计是依据sgRNA序列,在FcγRIIb基因序列上sgRNA序列的左右选择各加上55bp,并对sgRNA上的第18位的T突变成C,将Cas9识别的PAM(NGG)突变,通过同义突变将TGG突变成TAG,使得寡链不再被cas9识别靶向,获得的特异性的寡聚核苷酸单链序列为SEQ ID NO.2。
本发明鉴定兔的基因型的鉴定引物F序列为SEQ ID NO.3,鉴定兔的基因型的鉴定引物R序列为SEQ ID NO.4。
以下对本发明做进一步详细说明:
1.本发明的特异性sgRNA序列:上游:5’-ggcggtggtcactgggattg -3’
下游5’-caatcccagtgaccaccgcc -3’制备方法:根据在线网站(http://www.rgenome.net/cas-offinder/),针对兔FcγRIIb基因序列,针对人类SLE疾病位点设计突变,sgRNA由金斯瑞生物科技有限公司合成。
2.特异性的寡聚核苷酸单链:该单链设计是依据sgRNA序列,在FcγRIIb基因序列上sgRNA序列的左右选择各加上55bp,并对sgRNA上的第18位的T突变成C,将Cas9识别的PAM(NGG)突变,通过同义突变将TGG突变成TAG,使得寡链不再被cas9识别靶向,单链序列由金斯瑞生物科技有限公司合成。合成方法:采用固相亚磷酰胺三酯法,以商业化DNA合成仪为主要合成平台进行生产,将单个核苷酸进行连接,形成短链DNA,合成时从3’-5’方向进行,相邻的核苷酸通过3’-5’磷酸二酯键连接,通常3’端第一个碱基结合在CPG上。步骤:一般经过脱保护,活化缩合,盖帽和氧化四个步骤完成一个碱基的添加。
3.Cas9 mRNA的准备
(1)Cas9质粒线性化
3x FLAG-NLS-SpCas9-NLS 载体(Addgene ID:48137),经NotI酶线性化后,酶切体系(表1),37℃酶切过夜,取1 μL酶切产物进行1%琼脂糖凝胶电泳,以未酶切原质粒为对照,电泳鉴定线性化完全后,用DNA胶回收试剂盒回收酶切产物。
表1 Not I单酶切体系
。
(2)Cas9质粒体外转录
冰上解冻mMessage mMachine SP6 Kit (Ambion) 试剂盒中的相关液体,按照表2体系转录体系进行,将产物置于冰上,加入1 μL Tubro DNaseIII,放入37℃水浴,2小时,以除去残留的DNA转录产物,利用2%的琼脂糖凝胶电泳进行鉴定体外转录产物的完整性及稳定性。
表2 Cas9质粒体外转录体系
。
(3)Cas9质粒体外转录产物纯化
使用miRNeasy Mini Kit (Qiagen)纯化试剂盒,将体外转录合成的Cas9进行纯化,具体操作按试剂盒说明书进行:
①取体外转录产物,向管中补加RNase-free水至100 μL,轻吹混匀,再向其中加入350 mL Buffer RTL,及预冷的250 μL无水乙醇,混匀。
②将①步骤中混合好的液体倒入粉色纯化柱内,静置2 min,12000rpm离心15s,弃去收集管中废液,将纯化柱重新放回收集管中。
③向纯化柱内加入500 μL Buffer RPE,12000 rpm离心15 s,弃液体。重复此步骤一遍。
④将纯化柱放入空收集管中,12000 rpm离心1 min,室温干燥2 min。
⑤将纯化柱放于RNase-free1.5mL离心管中,悬滴30 μL RNase-free水,12000rpm离心2 min,离心管中即为纯化好的Cas9-mRNA。
⑥测定mRNA浓度,将mRNA浓度稀释至200 ng/μL,分装2 μL/管,放置在-80℃冰箱待用。
4.为获得足够数量兔受精卵,本实验采用超数排卵方案。选用雌性新西兰大白兔(6-8月龄),在发情期内经肌肉注射促卵泡激素(FSH)50 IU,以促进卵泡发育成熟,每12小时注射一次,连续注射3天。最后一次注射后,与公兔进行交配,将交配成功的供体母兔通过耳缘静脉注射100 IU人绒毛膜促性腺激素(HCG)。在注射18-20h后,将母兔耳缘静脉注射空气处死,剖开腹腔取出卵巢和输卵管放于培养皿中,使用冲卵液DPBS-BSA冲出受精胚胎,将胚胎移入培养液EBSS中,置于38.5℃,5% CO2饱和湿度的培养箱内孵育待用。
5.胚胎显微注射:将体外合成的FcγRIIb-sgRNA(50ng/UL)、单链DNA和Cas9mRNA(200ng/UL),短暂离心后混合,吸出3μL至注射针中,进行胚胎细胞核注射。注射后的受精卵(约30-50枚)移植到同期发情的受体母兔输卵管中,对代孕母兔提供充足的饲料和饮水,保持干净饲养环境,规范化饲养。妊娠至20天后,转至产房饲养至预产期。
6.兔基因型鉴定
提取组织的DNA,提取方法按照试剂盒说明书操作(天根,北京,中国),进行PCR及测序,确定基因型。
PCR 引物: 上游引物:GGAGGAAGTAAATAGTGCACAGA
下游引物:GGGACTAGACTTTATCTTGGTGTC
PCR反应体系
模板 1ul
上游引物 1ul
下游引物 1ul
2X taqplus 12.5 ul
二馏水 9.5ul
反应的条件:95℃预变性5min;95 ℃变性30s,58℃退火30s,72℃延伸27s;35个循环;72℃ 延伸5min。
PCR产物送于生工生物工程股份公司测序,若在sgRNA序列的第18位的T突变成C,则证明获得单碱基突变。
7.抗体水平检测
待基因修饰兔成长发育到8周龄,使用商品化兔瘟疫苗进行免疫,采用每隔7天进行免疫一次,按照每次免疫1ml的计量,并收集血清,收集的血清进行抗体效价检测,使用商品化兔瘟病毒ELISA抗体检测试剂盒进行操作,方法如下:
1)设置2个酶标孔中加入100ul阴性对照;
2)在2个酶标孔中加入100ul阳性对照;
3)将待检样品经1:20稀释后取100ul加入相应的孔中;
4)37℃孵育30min;
5)弃液体,每孔加入250ul的洗涤液进行洗板,重复5次,每次30s;
6)每孔加100ul酶标结合物;
7)37℃孵育30min,重复步骤5);
8)向每孔加入100ul底物液体;
9)37℃孵育15min(避光显色);
10)每孔加入50ul终止液;
11)于450nm波长处测定各孔的吸光度值,即OD450值。
序列表
<110> 吉林大学
<120> 提高多克隆兔抗体产生的方法
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> 兔(rabbit)
<400> 1
ggcggtggtc actgggattg 20
<210> 2
<211> 130
<212> DNA
<213> 兔(rabbit)
<400> 2
cttccccaga gccttcgtcc aacccagacg atgactcact ggtggtgacg attgtggcgg 60
tggtcactgg gactatggtc atggctactg ttgccatcgt agcagccttc gtctacctca 120
aacgcaggcg 130
<210> 3
<211> 23
<212> DNA
<213> 兔(rabbit)
<400> 3
ggaggaagta aatagtgcac aga 23
<210> 4
<211> 24
<212> DNA
<213> 兔(rabbit)
<400> 4
gggactagac tttatcttgg tgtc 24
Claims (1)
1.一种提高多克隆兔抗体产生的方法,其特征在于:其步骤是:
步骤一、获得足够数量兔受精卵:采用超数排卵方案,选用雌性新西兰大白兔,在发情期内经肌肉注射促卵泡激素50 IU,以促进卵泡发育成熟,每12小时注射一次,连续注射3天;最后一次注射后,与公兔进行交配,将交配成功的供体母兔通过耳缘静脉注射100 IU人绒毛膜促性腺激素;在注射18-20h后,将母兔耳缘静脉注射空气处死,剖开腹腔取出卵巢和输卵管放于培养皿中,使用冲卵液DPBS-BSA冲出受精胚胎,将胚胎移入培养液EBSS中,置于38.5℃,5% CO2饱和湿度的培养箱内孵育待用;
步骤二、胚胎显微注射:将体外合成的50ng/UL 的FcγRIIb-sgRNA、单链DNA和200ng/UL的Cas9mRNA,短暂离心后混合,吸出3μL至注射针中,进行胚胎细胞核注射,注射后的受精卵30-50枚移植到同期发情的受体母兔输卵管中,对代孕母兔提供充足的饲料和饮水,保持干净饲养环境,规范化饲养,妊娠至20天后,转至产房饲养至预产期;所述的FcγRIIb-sgRNA的引导序列的DNA序列如序列1所示,单链DNA的序列如下:
cttccccagagccttcgtccaacccagacgatgactcactggtggtgacgattgtggcggtggtcactgggactgtagtcatggctactgttgccatcgtagcagccttcgtctacctcaaacgcaggcg
步骤三、兔基因型鉴定:提取组织的DNA,进行PCR及测序,确定基因型,
PCR 引物: 上游引物:GGAGGAAGTAAATAGTGCACAGA
下游引物:GGGACTAGACTTTATCTTGGTGTC
PCR反应体系
模板 1ul
上游引物 1ul
下游引物 1ul
2X taqplus 12.5 ul
二馏水 9.5ul
反应的条件:95℃预变性5min;95 ℃变性30s,58℃退火30s,72℃延伸27s;35个循环;72℃延伸5min;
PCR产物测序,若在对应于sgRNA引导序列的第18位的T突变成C,则证明获得基因突变兔。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210684243.6A CN114875074B (zh) | 2022-06-17 | 2022-06-17 | 提高多克隆兔抗体产生的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210684243.6A CN114875074B (zh) | 2022-06-17 | 2022-06-17 | 提高多克隆兔抗体产生的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114875074A CN114875074A (zh) | 2022-08-09 |
CN114875074B true CN114875074B (zh) | 2023-10-24 |
Family
ID=82680771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210684243.6A Active CN114875074B (zh) | 2022-06-17 | 2022-06-17 | 提高多克隆兔抗体产生的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114875074B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041870B2 (en) * | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
-
2022
- 2022-06-17 CN CN202210684243.6A patent/CN114875074B/zh active Active
Non-Patent Citations (2)
Title |
---|
Defining the immunological phenotype of Fc receptor-like B (FCRLB) deficient mice: Confounding role of the inhibitory FcγRIIb;Keiji Masuda等;《Cellular Immunology》;第266卷;全文 * |
PREDICTED: Oryctolagus cuniculus low affinity immunoglobulin gamma Fc region receptor II (LOC100359306), transcript variant X1, mRNA, Accession No. XM_008264171.2.《Genebank数据库》.2016,序列部分. * |
Also Published As
Publication number | Publication date |
---|---|
CN114875074A (zh) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107043787B (zh) | 一种基于CRISPR/Cas9获得MARF1定点突变小鼠模型的构建方法和应用 | |
CN105039339A (zh) | 一种以RNA介导的特异性敲除绵羊FecB基因的方法及其专用sgRNA | |
CN106086229B (zh) | 鸡生长性状相关的分子标记及其鉴别方法和应用 | |
CN113957069B (zh) | 用于pAPN基因第736位和第738位氨基酸同时修饰的组合物及其应用 | |
CN109706184B (zh) | 自闭症模型犬的建立方法 | |
CN106282231B (zh) | 粘多糖贮积症ii型动物模型的构建方法及应用 | |
CN106119284A (zh) | 一种用于构建免疫缺陷动物模型的产品及其应用 | |
CN113604504A (zh) | 用于pAPN基因16外显子定点修饰的组合物及其应用 | |
CN107699571A (zh) | 一种猪生长抑素基因编辑位点及其应用 | |
CN114875074B (zh) | 提高多克隆兔抗体产生的方法 | |
CN110982910B (zh) | 一种与公猪繁殖性状相关的circRNA及应用 | |
CN117487855A (zh) | 通过对cd163靶向灭活来改善猪类健康的方法 | |
CN114891834B (zh) | 基于crispr技术制备高产抗体兔的方法 | |
CN111100877B (zh) | 肥厚型心肌病小鼠模型的制备方法及其应用 | |
CN114592075B (zh) | 一种黄鳝生殖细胞异种移植及移植后嵌合性腺的检测方法 | |
CN116515825A (zh) | 一种敲除斑马鱼ddx18基因的sgRNA组合及其应用 | |
CN114480497B (zh) | 一种ep400基因敲除斑马鱼心力衰竭模型的构建及其应用的方法 | |
CN110129320B (zh) | 一种获得基因编辑绵羊的方法及其专用sgRNA和Oligo DNA | |
CN115720874A (zh) | 养殖经济鱼类无肌间刺种质创制方法及应用 | |
CN111088373B (zh) | 绵羊prl基因插入/缺失多态性的检测引物对、试剂盒、方法和应用 | |
CN110438159A (zh) | 一种引发肌原纤维肌病的基因突变小鼠模型的构建方法 | |
CN113973779A (zh) | 一种人工诱导多倍体泥鳅的方法 | |
CN114686524B (zh) | 一种利用基因编辑生产1龄雌性黄鳍鲷的方法 | |
CN114774413B (zh) | 斑马鱼排卵障碍模型的构建方法、检测方法及应用 | |
CN110331172B (zh) | 基于CRISPR-Cas9系统构建白化仓鼠模型的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |